BLU-451 for Lung Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called BLU-451, alone and with chemotherapy, in patients with advanced cancers that have specific EGFR mutations. The drug works by blocking signals that make cancer cells grow.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are on anti-epileptic drugs, you must be on a stable dose for at least 14 days before joining the trial.
What data supports the effectiveness of the drug BLU-451 for lung cancer?
Research indicates that platinum-based combination chemotherapy, like those involving Carboplatin, can modestly increase survival time and improve symptoms in patients with non-small cell lung cancer. Additionally, combination chemotherapy is the standard of care for advanced cases, suggesting potential benefits when used with other drugs like BLU-451.12345
What safety data exists for BLU-451 and related treatments for lung cancer?
Eligibility Criteria
Adults (18+) with advanced cancers that have a specific mutation called EGFR Exon 20 insertion, based on testing. They should not have seizures and must be generally healthy with good organ function. The trial is open to those who've progressed after systemic therapy or can't tolerate it, except for primary brain tumors.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1 Treatment
Initial dose-escalation to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BLU-451, including combination with carboplatin and pemetrexed
Phase 2 Treatment
Evaluation of efficacy and safety of BLU-451 as monotherapy at RP2D in participants with NSCLC
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BLU-451
- Carboplatin
- Pemetrexed
Find a Clinic Near You
Who Is Running the Clinical Trial?
Blueprint Medicines Corporation
Lead Sponsor